WO2008137787A3 - Combination therapy with a compound acting as a platelet adp receptor inhibitor - Google Patents

Combination therapy with a compound acting as a platelet adp receptor inhibitor Download PDF

Info

Publication number
WO2008137787A3
WO2008137787A3 PCT/US2008/062561 US2008062561W WO2008137787A3 WO 2008137787 A3 WO2008137787 A3 WO 2008137787A3 US 2008062561 W US2008062561 W US 2008062561W WO 2008137787 A3 WO2008137787 A3 WO 2008137787A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination therapy
receptor inhibitor
adp receptor
compound acting
platelet adp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/062561
Other languages
French (fr)
Other versions
WO2008137787A2 (en
Inventor
Pamela B Conley
Patrick Andre
Uma Sinha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002684722A priority Critical patent/CA2684722A1/en
Priority to NZ581324A priority patent/NZ581324A/en
Priority to ES08747590.1T priority patent/ES2467468T3/en
Priority to EP08747590.1A priority patent/EP2146705B1/en
Priority to BRPI0811000-0A2A priority patent/BRPI0811000A2/en
Priority to HK10105391.2A priority patent/HK1138765B/en
Priority to AU2008247435A priority patent/AU2008247435A1/en
Priority to MX2009011755A priority patent/MX2009011755A/en
Priority to JP2010506696A priority patent/JP5439363B2/en
Priority to CN200880021658.3A priority patent/CN101686959B/en
Priority to EA200901442A priority patent/EA020045B1/en
Priority to KR1020097024870A priority patent/KR101509829B1/en
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of WO2008137787A2 publication Critical patent/WO2008137787A2/en
Publication of WO2008137787A3 publication Critical patent/WO2008137787A3/en
Priority to TNP2009000444A priority patent/TN2009000444A1/en
Priority to IL201826A priority patent/IL201826A/en
Anticipated expiration legal-status Critical
Priority to MA32375A priority patent/MA31396B1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing [4 (6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases.
PCT/US2008/062561 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet adp receptor inhibitor Ceased WO2008137787A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
NZ581324A NZ581324A (en) 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet adp receptor inhibitor
ES08747590.1T ES2467468T3 (en) 2007-05-02 2008-05-02 Combination therapy with a compound that acts as a platelet ADP receptor inhibitor
EP08747590.1A EP2146705B1 (en) 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet adp receptor inhibitor
BRPI0811000-0A2A BRPI0811000A2 (en) 2007-05-02 2008-05-02 COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATTER ADP RECEIVER INHIBITOR
HK10105391.2A HK1138765B (en) 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet adp receptor inhibitor
AU2008247435A AU2008247435A1 (en) 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet ADP receptor inhibitor
MX2009011755A MX2009011755A (en) 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet adp receptor inhibitor.
CN200880021658.3A CN101686959B (en) 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet ADP receptor inhibitor
JP2010506696A JP5439363B2 (en) 2007-05-02 2008-05-02 Combination therapy with compounds acting as platelet ADP receptor inhibitors
CA002684722A CA2684722A1 (en) 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet adp receptor inhibitor
KR1020097024870A KR101509829B1 (en) 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet adp receptor inhibitor
EA200901442A EA020045B1 (en) 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet adp receptor inhibitor
TNP2009000444A TN2009000444A1 (en) 2007-05-02 2009-10-23 Combination therapy with a compound acting as a plateletadp receptor inhibitor
IL201826A IL201826A (en) 2007-05-02 2009-10-29 Use of [4-(6-fluoro-7-methylamino-2,4-dioxo-l,4-dihydro-2 hquinazolin- 3- yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea in the manufacture of a medicament for use with a second therapeutic agent for treating a condition characterized by undesired thrombosis and pharmaceutical compositions and kits comprising the same
MA32375A MA31396B1 (en) 2007-05-02 2009-11-26 The combination therapy is an active compound as an inhibitor of platelet adp receptor.

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US60/915,649 2007-05-02
US91591107P 2007-05-03 2007-05-03
US60/915,911 2007-05-03
US94792107P 2007-07-03 2007-07-03
US60/947,921 2007-07-03
US97870007P 2007-10-09 2007-10-09
US60/978,700 2007-10-09

Publications (2)

Publication Number Publication Date
WO2008137787A2 WO2008137787A2 (en) 2008-11-13
WO2008137787A3 true WO2008137787A3 (en) 2009-02-05

Family

ID=39587017

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/062561 Ceased WO2008137787A2 (en) 2007-05-02 2008-05-02 Combination therapy with a compound acting as a platelet adp receptor inhibitor

Country Status (20)

Country Link
US (2) US20080279845A1 (en)
EP (2) EP2586439A1 (en)
JP (1) JP5439363B2 (en)
KR (1) KR101509829B1 (en)
CN (1) CN101686959B (en)
AU (1) AU2008247435A1 (en)
BR (1) BRPI0811000A2 (en)
CA (1) CA2684722A1 (en)
CO (1) CO6241105A2 (en)
EA (1) EA020045B1 (en)
EC (1) ECSP099775A (en)
ES (1) ES2467468T3 (en)
GT (1) GT200900283A (en)
IL (1) IL201826A (en)
MA (1) MA31396B1 (en)
MX (1) MX2009011755A (en)
NZ (2) NZ599556A (en)
PT (1) PT2146705E (en)
TN (1) TN2009000444A1 (en)
WO (1) WO2008137787A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2254385T3 (en) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. RELATED BENZAMIDS AND INHIBITORS OF FACTOR XA.
JP5020073B2 (en) 2004-06-18 2012-09-05 ミレニアム ファーマシューティカルズ インク． Factor Xa inhibitor
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
EP2774925B1 (en) 2005-11-08 2016-12-28 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of ATP-binding cassette transporters
US20090186810A1 (en) * 2006-03-27 2009-07-23 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EA015942B1 (en) * 2006-05-05 2011-12-30 Милленниум Фамэсьютикэлс, Инк. Substituted imidazoles, composition based thereon, a method for preventing or treating undesired thrombosis using thereof and method for inhibiting the coagulation of a blood sample
PT2077995E (en) * 2006-11-02 2012-05-10 Millennium Pharm Inc Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
EP2114930A2 (en) * 2007-01-05 2009-11-11 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
CN101743001B (en) * 2007-04-13 2013-02-06 千年药品公司 Combination anticoagulant therapy with compounds acting as factor XA inhibitors
HUE031913T2 (en) 2007-12-07 2017-08-28 Vertex Pharma 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamide) -3-methylpyridin-2-yl) benzoic acid solid forms
RU2011123377A (en) * 2008-11-14 2012-12-20 Портола Фармасьютиклз, Инк. SOLID COMPOSITION FOR CONTROLLED RELEASE OF ACTIVE IONIZABLE AGENTS CHARACTERIZED BY LOW SOLUBILITY IN WATER AT LOW pH VALVES AND METHODS OF ITS APPLICATION
WO2011084652A2 (en) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor
WO2011075602A1 (en) 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
ES2548845T3 (en) * 2009-12-23 2015-10-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor and acetylsalicylic acid
JP2013518034A (en) * 2010-01-21 2013-05-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Special composition for use as a drug
SMT201900650T1 (en) * 2010-02-25 2020-01-14 Pfizer Apixaban formulations
RS62767B1 (en) 2010-04-07 2022-01-31 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
TW201221128A (en) * 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
MX2013011266A (en) * 2011-03-29 2014-03-27 Sanofi Sa Benzoic acid salt of otamixaban.
US20150224091A1 (en) * 2011-08-31 2015-08-13 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
MX355183B (en) 2012-01-25 2018-04-09 Vertex Pharma ACID FORMULATIONS 3- (6- (1- (2.2- DIFLUOROBENZO [D] [1,3] DIOXOL-5-IL) CYCLOPROPANCARBOXAMIDE) -3- METHYLPIRIDIN-2-IL) BENZOIC.
EP2934538B1 (en) * 2012-12-19 2021-03-31 Merck Sharp & Dohme Corp. Factor ixa inhibitors
US9695198B2 (en) 2012-12-19 2017-07-04 Merck Sharp & Dohme Corp. Factor IXa inhibitors
US9914727B2 (en) 2012-12-19 2018-03-13 Merck Sharp & Dohme Corp. Factor IXa inhibitors
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
HRP20210516T2 (en) 2013-11-12 2021-10-01 Vertex Pharmaceuticals Incorporated PROCEDURE FOR PRODUCTION OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES
EP3104702B1 (en) * 2014-02-11 2022-08-10 Merck Sharp & Dohme LLC Factor xia inhibitors
CN106831553A (en) * 2015-09-11 2017-06-13 天津科伦药物研究有限公司 The preparation method of betrixaban or its analog
CN105250286A (en) * 2015-11-13 2016-01-20 谭惠娟 Antithrombotic composition
EP3254674A1 (en) * 2016-06-08 2017-12-13 Sandoz Ag Pharmaceutical compositions of betrixaban maleate
US10875851B2 (en) 2016-11-18 2020-12-29 Merck Sharp & Dohme Corp. Factor XIIa inhibitors
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020077486A1 (en) * 2000-02-04 2002-06-20 Scarborough Robert M. Platelet ADP receptor inhibitors
WO2007056219A2 (en) * 2005-11-03 2007-05-18 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440147B1 (en) * 1998-09-03 2002-08-27 Rubicor Medical, Inc. Excisional biopsy devices and methods
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6297233B1 (en) 1999-02-09 2001-10-02 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
DE60040676D1 (en) * 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDES AND SIMILAR INHIBITORS OF FACTOR Xa
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
ES2254385T3 (en) * 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. RELATED BENZAMIDS AND INHIBITORS OF FACTOR XA.
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7235567B2 (en) 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
EP2351855A1 (en) 2000-09-26 2011-08-03 Duke University RNA aptamers and methods for identifying the same
US7312235B2 (en) * 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
ZA200508481B (en) * 2003-04-09 2007-04-25 Japan Tobacco Inc Heteroaromatic pentacyclic compound and medicinal use thereof
JP4879745B2 (en) * 2003-10-03 2012-02-22 ポートラ ファーマシューティカルズ， インコーポレイテッド Substituted isoquinolinone
CN1886398A (en) * 2003-10-09 2006-12-27 米伦纽姆医药公司 Thioether-substituted benzamides as inhibitors of factor Xa
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
JP5020073B2 (en) * 2004-06-18 2012-09-05 ミレニアム ファーマシューティカルズ インク． Factor Xa inhibitor
CA2587026A1 (en) * 2004-10-25 2006-05-04 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
JP2008528691A (en) 2005-02-02 2008-07-31 ビテ ファーマシューティカルズ， インコーポレイテッド 1-Acylamino-2-hydroxy-3-amino-ω-arylalkanes as renin inhibitors
US7467697B2 (en) * 2005-10-07 2008-12-23 Ford Global Technologies, Llc Electromagnetic coupling device for engine accessories
RU2440986C2 (en) * 2005-11-08 2012-01-27 Милленниум Фамэсьютикэлс, Инк. FACTOR Xa INHIBITOR SALT, METHOD FOR MAKING IT, BASED PHARMACEUTICAL COMPOSITION, TABLET, CAPSULE AND LOZENGE CONSISTING OF THIS COMPOSITION, METHOD FOR TREATING THROMBOSIS AND METHOD FOR INHIBITING BLOOD SAMPLE COAGULATION
US20090186810A1 (en) * 2006-03-27 2009-07-23 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EA015942B1 (en) 2006-05-05 2011-12-30 Милленниум Фамэсьютикэлс, Инк. Substituted imidazoles, composition based thereon, a method for preventing or treating undesired thrombosis using thereof and method for inhibiting the coagulation of a blood sample
NZ578180A (en) * 2006-12-08 2012-02-24 Millennium Pharm Inc Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
EP2114930A2 (en) * 2007-01-05 2009-11-11 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
CN101743001B (en) * 2007-04-13 2013-02-06 千年药品公司 Combination anticoagulant therapy with compounds acting as factor XA inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020077486A1 (en) * 2000-02-04 2002-06-20 Scarborough Robert M. Platelet ADP receptor inhibitors
WO2007056219A2 (en) * 2005-11-03 2007-05-18 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Also Published As

Publication number Publication date
EP2146705B1 (en) 2014-03-05
MX2009011755A (en) 2010-02-12
MA31396B1 (en) 2010-05-03
US8946219B2 (en) 2015-02-03
IL201826A0 (en) 2010-06-16
WO2008137787A2 (en) 2008-11-13
ECSP099775A (en) 2010-01-29
CO6241105A2 (en) 2011-01-20
JP2010526103A (en) 2010-07-29
EA020045B1 (en) 2014-08-29
IL201826A (en) 2014-08-31
NZ599556A (en) 2013-10-25
KR20100023836A (en) 2010-03-04
TN2009000444A1 (en) 2011-03-31
BRPI0811000A2 (en) 2015-01-27
AU2008247435A1 (en) 2008-11-13
NZ581324A (en) 2012-05-25
CN101686959A (en) 2010-03-31
CA2684722A1 (en) 2008-11-13
EP2586439A1 (en) 2013-05-01
US20110033459A1 (en) 2011-02-10
HK1138765A1 (en) 2010-09-03
US20080279845A1 (en) 2008-11-13
PT2146705E (en) 2014-05-23
JP5439363B2 (en) 2014-03-12
EP2146705A2 (en) 2010-01-27
GT200900283A (en) 2011-10-05
CN101686959B (en) 2014-05-07
ES2467468T3 (en) 2014-06-12
EA200901442A1 (en) 2010-06-30
KR101509829B1 (en) 2015-04-06

Similar Documents

Publication Publication Date Title
MX2009011755A (en) Combination therapy with a compound acting as a platelet adp receptor inhibitor.
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
WO2006119507A3 (en) Non-nucleotide composition and method for inhibiting platelet aggregation
WO2012047017A3 (en) 2,3-dihydro-isoindol-1-one derivative and a composition comprising the same
WO2010108074A3 (en) Inhibitors of pi3 kinase
MX2009004716A (en) Compounds and compositions as protein kinase inhibitors.
EA200802118A1 (en) HAVING INHIBITING ACTIVITY WITH RESPECT TO MNK1 / MNK2 THYENOPYRIMIDINES INTENDED FOR USE IN PHARMACEUTICAL COMPOSITIONS
WO2009016410A3 (en) Chemical compounds 831
MY139689A (en) Imidazotriazines as protein kinase inhibitors
IL198979A (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2006066937A3 (en) Mnk1 or mnk2 inhibitors
WO2007115620A3 (en) Novel cyclobutyl compounds as kinase inhibitors
WO2008116139A3 (en) N-heterocyclic compounds useful as inhibitors of janus kinases
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2007120760A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
WO2008026156A3 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
WO2008128009A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2007056219A3 (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
WO2007110340A3 (en) Pyrimidine, quinazoline, pteridine and triazine derivatives
WO2009051718A3 (en) Calcium receptor modulating agents
MX2010003269A (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880021658.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08747590

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12009501982

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2684722

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008247435

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009101585

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 201826

Country of ref document: IL

Ref document number: 2010506696

Country of ref document: JP

Ref document number: MX/A/2009/011755

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 7079/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008747590

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 581324

Country of ref document: NZ

Ref document number: 09132196

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 200901442

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20097024870

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2009000704

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: PI 20094513

Country of ref document: MY

ENP Entry into the national phase

Ref document number: PI0811000

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091028